Arkema stands out from peers with over € 400m in potential EBITDA to be generated by fully financed projects. Unluckily, the macroeconomic environment, which caused the group to lose over € 200m in EBITDA, deteriorated further at the start of the year, with major uncertainties now weighing on the outlook. We are lowering our EPS estimates by 8% (2025-27 average). Our new target price, adjusted to € 85 from € 92 (6x 2025e pro forma EBITDA), still harbours significant upside (current price close t...
Arkema se distingue par une réserve d’EBITDA >400 M€ en provenance de projets déjà financés. Mais le contexte macro, à l’origine d’un manque à gagner >200 M€ d’EBITDA, continue de se dégrader en ce début d’année avec des incertitudes majeures. Nous abaissons nos BPA estimés de 8% (moyenne 2025-2027). Notre nouvel OC à 85 € vs 92 € (6x l’EBITDA 2025e proforma), offre toujours un potentiel significatif (cours actuel proche du scénario bear excluant toute reprise de la demande sur les prochaines an...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of Arkema S.A. and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 19 March 2025 in which we reassessed the appropriateness of the ratings in the context of the r...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.